Hematologic Malignancy
Acute Myeloid Leukemia with Genetic Abnormalities
CI-CAN-00004303Explore in graph →
Hematologic30 active trials2 approved drugs55 evidence items
- NCIt
- C224900
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004303Explore in graph →
Clinical trials
264 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (45)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07504458 | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia(QUATRO-APL) | recruiting | Phase 3 | 150 | Quetzal TherapeuticsINDUSTRY | 5 | Sep 23, 2026 | clinicaltrials |
| NCT07597941 | Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | not yet recruiting | Phase 2 / Phase 3 | 20 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jun 30, 2026 |
| clinicaltrials |
| NCT07503730 | Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).(EARLY-RIF APL) | recruiting | Phase 3 | 224 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02339740 | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | active not recruiting | Phase 3 | 158 | Children's Oncology GroupNETWORK | 6 | Feb 18, 2026 | clinicaltrials |
| NCT07296445 | A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)(LATITUDE) | not yet recruiting | Phase 3 | 120 | SDK Therapeutics, Inc.INDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT06544109 | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients(Ven APL) | enrolling by invitation | Phase 2 / Phase 3 | 98 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | not yet recruiting | Phase 3 | 312 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 0 | May 26, 2023 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials